• Hydrix Services revenue growth >10% and operating profit >10% in CY2025
• Medical segment to generate annual recurring revenues
• Venture capital gains expected from liquidity events

Hydrix Ltd, a global technology innovation company, has released its mid-year market update, showcasing the progress of its 'Buy, Build, Invest' strategy. The company's Services segment has demonstrated strong traction, with international revenues increasing from 25% in FY21 to 75% in FY24, supported by its expertise, global reputation, and focus on cardiovascular technologies. The Medical segment is poised for growth, with a suite of innovative cardiac diagnostic and remote patient monitoring products being brought to market, including a real-time heart attack warning device, remote patient monitoring solutions, and AI-based heart disease diagnosis tools. Hydrix Ventures continues to selectively invest in clients developing breakthrough technologies, targeting liquidity events as a source of non-dilutive funds to support expansion and debt reduction. The company reported a Group 1HFY25 cash operating loss of $0.4 million, a significant improvement from the $2.1 million loss in the prior corresponding period, reflecting reduced costs and improved margins. Key CY2025 objectives include growing Services revenue and operating profit, generating annual recurring revenues in the Medical segment, and seeking opportunistic liquidity events from the Ventures portfolio.

Hydrix Services revenue growth >10% and operating profit >10% in CY2025. The Medical segment is expected to generate annual recurring revenues.

Hydrix is focused on growing its Services and Medical segments to drive profitability, while seeking opportunistic liquidity events from its Ventures portfolio to fund growth and pay down debt.